TNF and autoimmune disease: Additionally, prolonged use of TNF-α inhibitors may cause in some patients the development of anti-drug antibodies (i.e., adalimumab), thus promoting adverse effects and reducing drug efficacy; other studies revealed that induced autoantibodies, clinically manifest autoimmune diseases, and paradoxical inflammation may also occur as a result of administered TNF-α inhibitors [21].